Alnylam Pharmaceuticals, Inc. (ALNY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY)

ALNY 456.04

+1.5%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: A.J. Mullen	6/24/2024 1:14:19 PM
	Read Replies (1) of 166

Good results from a Phase 3 trial of Vutrisaran, an RNAi therapy against ATTR cardiomyopathy, give 35% boost to shares of Alnylam. It reduced deaths and recurrent CV events compared to both a placebo and standard of care (tafamidis). wsj.com finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next